Merck is acquiring an Israeli biopharmaceutical company for $95 million in cash, the drugmaker announced Tuesday.

The Kenilworth-based company’s deal for cCAM Biotherapeutics, which is focused on cancer immunotherapies, could potentially include up to $510 million in milestone payments, it said.

“We continue to strengthen our portfolio of immunotherapeutic candidates through strategic collaborations and acquisitions,” Dr. Roger M. Perlmutter, president of Merck Research Laboratories, said in a prepared statement. “The acquisition of cCAM supports our objective to advance the care of patients with cancer by stimulating tumor-directed immune responses.”

Read the rest of the article here.